A Phase 2, Multi-Center, Open-label, Randomized, Parallel-Dose Study to Determine the Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension (PAH)
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 29
- 试验地点
- 25
- 主要终点
- Change in pulmonary vascular resistance (PVR)from baseline to week 16 assessed at peak AIR001
研究概览
简要总结
The purpose of this study is to evaluate the safety and effectiveness of an investigational/experimental drug called AIR001.
To test the effectiveness, the study will evaluate how AIR001 affects the blood vessels in the lungs and the function of the heart. This will be done by monitoring changes in Pulmonary Vascular Resistance (PVR); from Baseline/Day 1 (start of study drug) to Week 16 of the study. PVR measures the resistance to flow in the blood vessels of the lungs. The study will include other assessments to evaluate the effect of the study drug on PAH, including measurements of exercise ability and evaluations of PAH disease symptoms.
详细描述
The primary objective of this study is to evaluate the efficacy of inhaled nebulized AIR001 administered, for 16 weeks, according to 3 treatment arms (80 mg once daily, 46 mg 4 times daily, or 80 mg 4 times daily) in subjects with World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH), as determined by change in Pulmonary Vascular Resistance (PVR) from Baseline to Week 16 measured immediately post completion of AIR001 nebulization (as soon as feasible).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed and dated informed consent document
- •Able to comply with study procedures
- •Diagnosis of PAH as classified by:
- •Idiopathic (IPAH) or heritable(HPAH); or
- •PAH associated with CTD; Systemic Sclerosis, Limited Scleroderma, Mixed, SLE, or overlap syndrome;
- •PAH associated with HIV ii. Simple, congenital shunts at least one year post repair. iii. Exposure to legal drugs, chemicals and toxins
- •Cardiac catheterization prior to Screening with:
- •mPAP ≥ 25 mmHg (at rest);
- •PCWP ≤ 15 mmHg; and
- •PVR > 3 mmHg/L/min or 240 dyn.sec/cm5
- •A qualification cardiac catheterization, to confirm the persistence and severity of PAH, if the diagnostic catheterization was performed more than 30 days prior to Baseline
- •Confirms diagnosis;
- •PVR above 300 dyn.sec/cm5 to demonstrate the persistence and severity of PAH; and
- •No change in disease-specific PAH therapy since the qualification catheterization used
- •Newly diagnosed PAH on no disease-specific PAH therapy or previously diagnosed on oral disease-specific PAH therapy for 90 days prior with either an ETRA and/or PDE-5i
- •Has PFTs within 180 days prior to Baseline with no evidence of significant parenchymal lung disease defined as:
- •FEV1 ≤ 70% (predicted) (pre-bronchodilators);
- •FEV1/FVC ≤ 70% (pre-bronchodilators); or
- •Total lung capacity < 70% (predicted).
- •Has WHO/NYHA FC II- IV.
- •≥ 18 and ≤ 75 years.
- •Weight ≥ 40 kg.
- •Has 6MWT distance at least 50 meters.
- •Had a V/Q scan or pulmonary angiogram prior to Screening that shows no evidence of thromboembolic disease
- •If on the following: vasodilators (including calcium channel blockers), digoxin, spironolactone, or L-Arginine; must be on a stable dose 30 days prior to Baseline and maintained throughout the study
- •If on corticosteroids, has been receiving a stable dose of ≤ 20 mg/day of prednisone (or equivalent dose, if other corticosteroid) for at least 30 days
- •Women of childbearing potential must be using at least one form of medically acceptable contraception. Women who are surgically sterile or those who are post-menopausal for at least 2 years are not considered to be of childbearing potential. Men who are not sterile must also agree to use contraception
排除标准
- •Participation in a device or other interventional clinical studies, within 30 days of Baseline and during study participation
- •Participation in a cardio-pulmonary rehabilitation program based upon exercise within 30 days prior to Baseline and/or during the study
- •Has uncontrolled systemic hypertension: SBP > 160 millimeter of mercury (mmHg) or DBP > 100 mmHg during Screening
- •SBP < 90 mmHg at Screening or Baseline
- •History of orthostatic hypotension or at the time of Screening; defined as a drop in SBP by ≥ 20 mmHg or DBP of ≥ 10 mmHg during Screening
- •History of left-sided heart disease and/or clinically significant cardiac disease, including:
- •Aortic or mitral valve disease (stenosis or regurgitation) defined as greater than mild;
- •Pericardial constriction;
- •Restrictive or congestive cardiomyopathy;
- •Left ventricular ejection fraction < 40%
- •Left ventricular shortening fraction < 22% by ECHO prior to Screening;
- •Symptomatic coronary disease
- •Significant (2+ for regurgitation) valvular disease other than TR or PR
- •Acutely decompensated heart failure within 30 days prior to Baseline
- •History of atrial septostomy within 180 days prior to Baseline
- •History of obstructive sleep apnea (treated, untreated or resolved)
- •Diagnosis of Down syndrome
- •Moderate to severe hepatic impairment
- •Has chronic renal insufficiency as defined by serum creatinine > 2.5 mg/dL or has an eGFR < 30 mL/min at Screening, or requires dialysis
- •Has a Hgb concentration < 8.5 g/dL at Screening
- •Personal or family history of the following:
- •Congenital or acquired methemoglobinemia;
- •RBC CYPB5 reductase deficiency
- •G6PD deficiency or any contraindication to receiving methylene blue
- •For subjects with HIV any of the following:
- •Concomitant active opportunistic infections 180 days prior to Screening;
- •Detectable viral load within 90 days of Screening;
- •T-cell count < 200 mm3 within 90 days of Screening;
- •Changes in antiretroviral regimen within 90 days of Screening;
- •Using inhaled pentamidine
- •Receiving chronic treatment with prostacyclin/prostacyclin analogue within 60 days of Baseline
- •Requirement of intravenous inotropes within 30 days prior to Baseline
- •The use of oral or topical nitrates (nitroglycerin, glyceryl trinitrate (GTN), isosorbide dinitrate, and isosorbide mononitrate) within 30 days prior to Baseline and until EOS or Termination
- •Known or suspected hypersensitivity or allergic reaction to sodium nitrite or sodium nitrate
- •History of malignancy within 5-years prior to Baseline
- •Other severe acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation
- •Has a disorder that compromises the ability to give informed consent
- •Is currently pregnant or breastfeeding or intends to become pregnant
- •Investigators, study staff or their immediate families
研究组 & 干预措施
80mg AIR001 four times daily
80mg AIR001 nebulized four times daily for 16 weeks
干预措施: AIR001 (sodium nitrite inhalation solution) (Drug)
46mg AIR001 four times daily
46mg AIR001 nebulized four times daily for 16 weeks
干预措施: AIR001 (sodium nitrite inhalation solution) (Drug)
80mg AIR001 once daily
80mg AIR001 nebulized once daily for 16 weeks
干预措施: AIR001 (sodium nitrite inhalation solution) (Drug)
结局指标
主要结局
Change in pulmonary vascular resistance (PVR)from baseline to week 16 assessed at peak AIR001
时间窗: 16 weeks
The primary objective of this study is to evaluate the efficacy of inhaled nebulized AIR001 administered, for 16 weeks, according to 3 treatment arms (80 mg once daily, 46 mg 4 times daily, or 80 mg 4 times daily) in subjects with World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH), as determined by change in Pulmonary Vascular Resistance (PVR) from Baseline to Week 16 measured immediately post completion of AIR001 nebulization (as soon as feasible).
次要结局
- Time to Clinical Worsening (TTCW), other hemodynamics, and safety(16 weeks)